National Comprehensive Cancer Network

About NCCN

NCCN Flash Updates™: NCCN Guidelines® & NCCN Compendium® Updated

NCCN has published updates to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) and the NCCN Drugs & Biologics Compendium (NCCN Compendium®) for Acute Lymphoblastic Leukemia. These NCCN Guidelines® are currently available as Version 1.2015.

  • Patients in Complete Response (CR) following treatment with induction therapy (ALL-3 through ALL-6)
    • “Consider” was removed before “Monitoring for Minimal residual disease (MRD).”
  • Content for the Management of Asparaginase Toxicity replaced (ALL-B 3 of 4 and ALL-B 4 of 4)
  • Induction regimens for Ph-negative ALL (ALL-D 2 of 4)
    • The following regimen added for Pediatric-inspired protocols for AYA patients aged 15–39 years:
      “USC ALL regimen based on CCG-1882 regimen: daunorubicin, vincristine, prednisone, and methotrexate with augmented  pegaspargase (patients aged 18–57 years)”
  • Regimens for relapsed/refractory Ph-positive ALL (ALL-D 3 of 4)
    • The following bullet added: “The TKIs noted above may also be used in combination with any of the induction regimens noted on ALL-D 1 of 4 that were not previously given.”

For the complete updated versions of the NCCN Guidelines, the NCCN Compendium®, and the NCCN Chemotherapy Order Templates (NCCN Templates®), please visit NCCN.org.

To access the NCCN Biomarkers Compendium®, please visit NCCN.org/biomarkers.

To view the NCCN Guidelines for Patients®, please visit NCCN.org/patients.

Free NCCN Guidelines apps iPhone, iPad, and Android devices are now available! Visit NCCN.org/apps

About NCCN Flash Updates™ 

NCCN Flash Updates™ is a subscription service from NCCN that provides timely notification of updated and new information appearing in the NCCN Guidelines, the NCCN Compendium, and other NCCN Content. 

Subscribe to NCCN Flash Updates™ 

National Comprehensive Cancer Network® (NCCN®)

275 Commerce Drive, Suite 300

Fort Washington, PA 19034

Telephone: +1 215.690.0300 Fax: +1 215.690.0280 

Access information on permissions and licensing of NCCN Content  

© 2015 National Comprehensive Cancer Network. All Rights Reserved.